Reported Saturday, Daiichi Sankyo And Merck's Ifinatamab Deruxtecan Shows Response Rates In Extensive-Stage Small Cell Lung Cancer In Phase 2 IDeate-Lung01 Trial
Reported Saturday, Daiichi Sankyo And Merck's Ifinatamab Deruxtecan Shows Response Rates In Extensive-Stage Small Cell Lung Cancer In Phase 2 IDeate-Lung01 Trial
周六报道，默沙东和黛印创对于小基站5g肺癌晚期的响应率在第2阶段Idate-Lung01试验中显示
- Objective response rate of 54.8% seen with Daiichi Sankyo and Merck's ifinatamab deruxtecan at 12 mg/kg dose in pretreated patients
- 12 mg/kg selected as optimal dose for extension part of IDeate-Lung01 phase 2 trial and recently initiated IDeate-Lung02 phase 3 study
- 在预先治疗的患者中，第一三共和默克的ifinatamab deruxtecan在12 mg/kg剂量下的客观缓解率为54.8％
- 12 mg/kg 被选为 Ideate-Lung01 2 期试验延期部分的最佳剂量，最近启动了 Ideate-Lung02 3 期研究
资讯热榜
更新时间